Groupama Asset Managment Trims Stake in Denali Therapeutics Inc. $DNLI

Groupama Asset Managment reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 22.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 135,758 shares of the company’s stock after selling 39,773 shares during the period. Groupama Asset Managment owned 0.09% of Denali Therapeutics worth $1,971,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Headlands Technologies LLC bought a new stake in Denali Therapeutics during the 2nd quarter valued at approximately $26,000. Johnson Financial Group Inc. bought a new position in shares of Denali Therapeutics in the 3rd quarter worth approximately $29,000. State of Wyoming bought a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $29,000. Quarry LP purchased a new position in shares of Denali Therapeutics in the 3rd quarter valued at approximately $64,000. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Denali Therapeutics by 120.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,236 shares of the company’s stock valued at $115,000 after purchasing an additional 4,494 shares during the period. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on DNLI shares. UBS Group started coverage on Denali Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating on the stock. BTIG Research raised their price objective on Denali Therapeutics from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Wedbush dropped their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price target on shares of Denali Therapeutics in a research note on Thursday, January 8th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.20.

Insider Buying and Selling at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $580,767.00. Following the completion of the transaction, the chief executive officer owned 296,833 shares of the company’s stock, valued at $4,897,744.50. The trade was a 10.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the transaction, the insider owned 282,828 shares in the company, valued at approximately $4,666,662. The trade was a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. 12.50% of the stock is owned by company insiders.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $19.75 on Friday. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $23.77. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $3.13 billion, a P/E ratio of -6.65 and a beta of 1.02. The stock’s 50 day moving average is $20.14 and its 200 day moving average is $17.62.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.02. During the same period in the previous year, the firm posted ($0.67) EPS. On average, equities research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.